HOME >> BIOLOGY >> NEWS
University Of Kentucky Researcher Awarded MERIT Extension For Study Of Third World Killer

LEXINGTON, KY (Sept. 21, 1998) - Salvatore Turco, Ph.D., professor of biochemistry, University of Kentucky College of Medicine, has received a five-year extension on a National Institutes of Health (NIH) Method to Extend Research in Time (MERIT) award. The National Institute of Allergy and Infectious Diseases at the NIH has awarded Turco $1,583,700 to continue his study, "Glycoconjugates of Leishmania."

Leishmania donovani, a one-cell parasite, is one of the world's major pathogens. It afflicts 10 to 20 million people in Mediterranean and Third World countries. The parasite is transmitted by sand flies and results in the disease called leishmaniasis. Leishmaniasis, which often results in death, is a problem for residents, travelers, and U.S. soldiers stationed in the Middle East. It was a particular issue during Desert Storm, Turco said. Symptoms include sores, high fever and severe disfigurement. There are only antiquated drugs used for cures and preventive measures, despite scientists' understanding of the biology of the parasite's attack on the human body.

"We are trying to determine how the parasite survives in the human host," Turco said. "We suspect there is something unusual about the Leishmania cell surface that we feel is responsible for the parasite to invade the body and survive with impunity."

Leishmania's cell surface contains a complex molecule made up of sugar, fat and phosphate, called a lipophosphoglycan, that is used for defensive purposes. The molecule prevents the host animal's white cells, called macrophages, from being activated and attacking the parasite. Without the lipophosphoglycan, the parasite is destroyed by macrophages.

Researchers hope that the molecule might play a key role in creating treatments or preventive therapies for leishmaniasis.


'"/>

Contact: Kim Cumbie
krcumb0@pop.uky.edu
(606) 323-6363
University of Kentucky Medical Center
22-Sep-1998


Page: 1

Related biology news :

1. Indiana University, EPA to study airborne PCBs
2. University of Alberta researcher looks for clues to mysterious disease
3. Northeastern University receives $12.4 million NSF grant for creation of nanomanufacturing institute
4. Washington University in St. Louis leads group studying aging process
5. Tufts University establishes $4 million dollar tissue engineering resource center
6. Case for IBD combination therapy comes from research at Baylor, MIT and Hebrew University
7. As informatics grows, Indiana University helps set research agenda
8. University of Arizona licenses patent for natural fungicide
9. Washington University in St. Louis plays key role in sequencing moss genome
10. University of Pittsburgh receives $10 million grant for head and neck cancer
11. Clemson University spin-off uses corn to make plastics, provide cleaner air

Post Your Comments:
(Date:11/3/2014)... Research and Markets has announced the addition of a ... to their offering. This report describes ... started to play an important role in the practice of ... bone marrow transplants. Role of cells in drug discovery is ... of medical practice. Stem cells are discussed in ...
(Date:11/3/2014)... , Nov. 3, 2014  NeuroSigma ® ... -based life sciences company focused on commercialization of ... for the treatment of neurological and neuropsychiatric ... Industrial Property has issued a Notice of Allowance ... application is co-owned by NeuroSigma and the Regents ...
(Date:11/2/2014)... , James Dacey explores the ways in which physicists ... innovations from the lab into the commercial market. , ... companies as they move from prototype to product is ... physics-based inventions are usually far from market-ready when initially ... lot more complicated than had been originally thought. , ...
Breaking Biology News(10 mins):Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 2Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 3NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 2NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 3The 'valley of death' facing physics start-ups 2
(Date:11/21/2014)... York, NY (PRWEB) November 20, 2014 ... is now available as an open access journal featuring ... with infrared fluorescent proteins to preserve photoresponsiveness in the ... Two-color fluorescent in situ hybridization using chromogenic substrates ... chips for DNA, RNA, and protein electrophoresis , ...
(Date:11/21/2014)... 21, 2014 2014 Deep Research ... is a professional and in-depth research report on ... information, like its definition, classification, application, and ... This report covers the international market analysis, including ... as the US, Europe, Asia, China, Japan etc. ...
(Date:11/21/2014)... Nov. 20, 2014 /CNW/ - Aequus Pharmaceuticals Inc. ... that it has closed a brokered private placement ... approximately C$3.7 million.  Cormark Securities Inc. and Clarus ... Brokered Offering for a syndicate of agents that ... Corp. (collectively the "Agents"). Concurrently with the Brokered ...
(Date:11/18/2014)... Nov. 18, 2014 Cord Blood Registry® (CBR®) ... the 10th Annual World Stem Cell Summit, the largest global ... 2014 World Stem Cell Summit will be held December 3-5 ... . The World Stem Cell ... lifesaving cures and therapies, convening the most prominent figures in ...
Breaking Biology Technology:BioTechniques: The International Journal of Life Science Methods Announces the Publication of the November 2014 Issue—Available in Print and Online 2BioTechniques: The International Journal of Life Science Methods Announces the Publication of the November 2014 Issue—Available in Print and Online 3Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 2Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 3Aequus Pharmaceuticals closes $4.2 million private placement financing 2Aequus Pharmaceuticals closes $4.2 million private placement financing 3Cord Blood Registry Sponsors 2014 World Stem Cell Summit 2Cord Blood Registry Sponsors 2014 World Stem Cell Summit 3
Cached News: